• Cost Curve
  • Posts
  • Pfizer Goes Deep on the Hows and Whys of the $1 Billion Part D Redesign Impact

Pfizer Goes Deep on the Hows and Whys of the $1 Billion Part D Redesign Impact

Plus Noom plugs into Lilly’s pharm-to-table ecosystem

Author

Brian Reid
March 31, 2025

logo

Subscribe to Cost Curve Apex to read the rest.

Upgrade to Apex to get access to this post and other subscriber-only content.

Upgrade
Already a subscriber?Sign in.

Everything drug pricing and policy, every day.

Posts Author

© 2025 Brian Reid.

Privacy policy

Terms of use

Powered by beehiiv